Investors rotating into cheaper stocks with more upside should ultimately benefit Rocket Lab and AST SpaceMobile. Both have already suffered major drawdowns. x.com 

Rocket Lab's program delays carry a financing cost, not just a later date, because development spending continues while expected customer cash moves out. In a September sensitivity, a $1.25B equity raise at $70 would issue about 17.9M shares, while at $50 it would take 25M, about 7.1M more; this is not a price forecast or a predicted raise. Even with eventual technical success, bridging a longer gap on worse terms could leave existing shareholders owning less of the result. x.com 

Rocket Lab's fundamentals do not yet justify buying, even after a 55% drop took it to around its 200-day moving average. It still lacks positive earnings, net income and growing free cash flow. The upside could be significant if the business executes over the next few years, but more proof of profitability is needed first; it stays on the watch list. x.com  x.com 

Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Rocket Lab will be a good investment because it does much more than launch rockets, though AST SpaceMobile looks like the better one. x.com 

Rocket Lab still looks ridiculously expensive at 29 times forward sales against SpaceX at 22 times, even after a 65% fall. At 22 times, Rocket Lab would be roughly $38, and SpaceX would still be the pick. SpaceX also has better forward guidance; Rocket Lab's negative adjusted EBITDA makes sales multiples the valuation yardstick. x.com  x.com  x.com  x.com 

Good SpaceX earnings could help Rocket Lab lead the new-space sector higher with a rally as violent as its capitulation. Rocket Lab is the sector leader outside SpaceX; its RSI is extremely oversold, the lower Bollinger band is overstretched and MACD's negative divergence is subsiding. Three upside gaps lie at $55.25-59.18, $64.22-65.71 and $73.11-74.76. The highest should fill before year-end, though the exact date is hard to predict. x.com  x.com 

Rocket Lab is underestimated as a launch company when it is building a broader space infrastructure business, where satellites, components, spacecraft systems and national-security demand could matter as much as launches. It just signed its largest commercial Electron deal by mission count, 20 launches for Synspective from 2028 to 2031, per Wall St Engine, pushing its launch backlog above 100 missions. x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab is a great company worth owning at a discount, and its elevated volatility pays well to wait for one. It is the only US public rocket company at scale, its backlog grows every quarter and revenue is up 55% year over year. Its implied volatility is among the highest in the space sector, with IV rank above 60%, while weekly EMA clouds are green and daily RSI just hit 44. x.com